Investigational drug · Phase 2
FB704A
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Severe Asthma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "FB704A"
First trial start
2021
Sep 30, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FB704A", any sponsor or status.
Conditions studied
As listed on its trial records.
- Severe Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "FB704A" as an intervention, largest first.
Fountain Biopharma Inc.Industry
NCT03890302 · 31 participants · Start Mar 14, 2019 · Primary completion May 27, 2020
Drug: FB704A; Placebo · For: Rheumatoid Arthritis
Sites: Overland Park, Kansas
Oneness Biotech Co., Ltd.Industry
NCT05018299 · 21 participants · Start Sep 30, 2021 · Primary completion May 8, 2026
Drug: FB704A placebo; FB704A · For: Severe Asthma
Sites: Kaohsiung City, Taiwan; Taichung, Taiwan; Taipei, Taiwan · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Severe Asthma
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- GB-0895Phase 32 trials
Generate Biomedicines · Severe Asthma
- VerekitugUPB-101Phase 24 trials
Upstream Bio Inc. · Severe Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- FrevecitinibPhase 21 trial
Kinaset Therapeutics Inc · Severe Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.